Table 4.
Tumour incidence and statistical analysis results derived from B6C3F1 mice from 2‐year carcinogenicity assays with furan
| Tumoura | Dosage (mg/kg bw per day) | Incidenceb | Reference | |
|---|---|---|---|---|
| Male | Female | |||
| Hepatocellular adenoma |
0 0.5 1.0 2.0 4.0 8.0 |
– |
3/36 4/72 4/53 4/41 11/36* 25/39*** |
Moser et al. (2009) |
| Hepatocellular carcinoma |
0 0.5 1.0 2.0 4.0 8.0 |
– |
0/36 4/72 2/53 1/41 2/36 11/39*** |
Moser et al. (2009) |
| Hepatocellular adenoma or carcinoma |
0 0.5 1.0 2.0 4.0 8.0 |
– |
3/36 8/72 6/53 5/41 12/36* 29/39*** |
Moser et al. (2009) |
| Hepatocellular carcinoma |
0 8 15 |
7/50 32/50*** 34/50*** |
2/50 7/50 27/50*** |
NTP (1993) |
| Hepatocellular adenoma |
0 8 15 |
20/50 33/50** 42/50*** |
5/50 31/50*** 48/50*** |
NTP (1993) |
| Benign Pheochromocytoma |
0 8 15 |
1/49 6/50 10/50*** |
2/50 1/50 6/50 |
NTP (1993) |
| Hepatocellular adenoma/carcinoma |
0 8 15 |
26/50 44/50*** 50/50*** |
7/50 34/50*** 50/50*** |
NTP (1993) |
bw: body weight.
a
Only the major tumour sites and/or those showing significant effects at the lower dose are listed.
b
*Equals significant at > 0.05; **equals significant at > 0.01; ***equals significant at > 0.001.